Loading patent…
AssigneesBiogaia AB, Board of Regents, The University of Texas System
InventorsStefan Roos, Yuying Liu, Baokun He, Jon Marc Rhoads
Estimating the term…
The present invention provides the use of inosine in the treatment of a disease associated with Treg deficiency or Treg dysfunction, in particular immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX). In one embodiment of the invention, the inosine can be provided in the form of a bacterial strain that is capable of stimulating the production of inosine. Methods for stimulating the production of inosine in a subject using said strains are also provided, as are methods for the selection of a bacterial strain capable of stimulating inosine production in a subject.
-10. (canceled)
A method for stimulating the production of inosine in a subject, said method comprising administering a lactic acid bacterial strain, wherein said strain is capable of stimulating the production of inosine, to said subject in an amount effective to stimulate production of inosine in said subject.
An in vivo method for selecting a lactic acid bacterial strain capable of stimulating inosine production, wherein said method comprises screening a bacterial strain for its ability to stimulate inosine production in vivo, and selecting a strain which has the ability to stimulate inosine production in vivo.
A method of treating a disease associated with Treg deficiency or Treg dysfunction comprising administration of a lactic acid bacterial strain, wherein said strain is capable of stimulating the production of inosine, to a subject having a disease associated with Treg deficiency or Treg dysfunction, in an amount effective to treat said disease.
-24. (canceled)
Dependencies are inferred from the claim text.